Loading
Life sciences · Journal article
Jurnal Sago Gizi Dan Kesehatan · August 7, 2026
Encouraging direction, but not yet definitive.
This systematic review of 10 RCTs found that probiotic supplementation shows potential benefits for gut microbiota composition and obesity-related metabolic parameters in overweight and obese adults, but the effects are heterogeneous and strongly dependent on strain, dose, duration, and population characteristics. The authors acknowledge that evidence is insufficient for strong recommendations and call for larger, longer-duration trials to establish efficacy and identify optimal probiotic formulations.
Systematic review of randomized controlled trials. Randomized controlled trials of overweight or obese adult participants receiving probiotic supplementation. Intervention: Probiotic supplementation (specific strains, doses, and durations varied across included studies). Compared with: Placebo or control group.
Eight of 10 studies reported improvements in gut microbiota composition or diversity Six of 10 studies showed reductions in LPS or inflammatory markers Nine of 10 studies reported improvements in at least one anthropometric or metabolic parameter (body weight, BMI, waist circumference, visceral fat, lipid profile)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
While probiotic supplementation shows promise for improving microbiota dysbiosis and metabolic health in overweight/obese patients, the variability in results means that clinicians cannot yet recommend a specific probiotic strain or formulation as standard practice. Further large-scale, longer-duration trials are needed before probiotics can be considered a robust adjunctive therapy.
A systematic review of 10 RCTs shows consistent but variable benefits of probiotics on microbiota and metabolic parameters in overweight/obese adults, but heterogeneity in strains, doses, and durations limits definitive conclusions.
As stated by the source record.
Quoted from the source exactly as published.
While probiotic supplementation shows promise for improving microbiota dysbiosis and metabolic health in overweight/obese patients, the variability in results means that clinicians cannot yet recommend a specific probiotic strain or formulation as standard practice. Further large-scale, longer-duration trials are needed before probiotics can be considered a robust adjunctive therapy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Obesity is a global public health problem whose prevalence continues to rise and is associated with various metabolic complications. Obesity is closely linked to gut microbiota dysbiosis, characterized by reduced microbial diversity, increased intestinal permeability, and low-grade chronic inflammation. Probiotics are considered to have potential as a complementary therapy because they can modulate the composition of the gut microbiota and improve metabolic health. However, evidence from randomized controlled trials (RCTs) regarding the effectiveness of probiotics still shows varying results due to differences in strains, doses, duration of intervention, and characteristics of the study subjects.Objectives: This review aimed to analyze the effects of probiotic supplementation on gut microbiota composition, markers of inflammation or intestinal permeability, and anthropometric and metabolic parameters in overweight and obese adults based on randomized controlled trials.Methods: A systematic literature review was conducted according to the PRISMA 2020 guidelines. A literature search was performed in PubMed, Scopus, Web of Science, and the Cochrane Library until April 2026. The included studies were randomized controlled trials involving overweight or obese adults who received probiotic supplementation compared to a placebo or control group. Study selection was performed independently by two reviewers. The risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, and the data were synthesized narratively. Results: Of the 10 included studies, eight reported improvements in gut microbiota composition or diversity, six showed reductions in LPS or inflammatory markers, and nine reported improvements in at least one anthropometric or metabolic parameter (body weight, BMI, waist circumference, visceral fat, and lipid profile). However, the effects of probiotics were not consistent across all studies and were strongly influenced by the strain, dose, duration, and population characteristics.Conclusion: Probiotic supplementation has potential benefits for improving gut microbiota dysbiosis and obesity-related metabolic parameters. However, further large-scale studies with longer intervention durations are required to confirm the long-term efficacy and identify the most effective probiotic strains.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.